- •Chapter 1
- •Ocular Adnexal Lymphoproliferative
- •1.1 Pathogenesis
- •1.2 Chronic Antigen Stimulation
- •1.3 Immunosuppression
- •1.4 Pathology
- •1.5 Cytogenetics
- •1.6 Clinical Features
- •1.7 Imaging Findings
- •1.8 Staging
- •1.9 Positron Emission Tomography
- •1.10 Treatment
- •1.11 Follicular Lymphoma
- •1.12 Mantle Cell Lymphoma
- •1.13 Radiotherapy
- •1.14 Chemotherapy
- •1.15 Immunotherapy
- •1.16 Radioimmunotherapy
- •1.17 Outcome
- •1.18 The Future
- •References
- •Chapter 2
- •2.1 General Introduction
- •2.2 The Aging Process and Facial Analysis
- •2.3 Endoscopic Brow Lift
- •2.3.1 Introduction
- •2.3.2 Endoscopic Browlift Anesthesia Pearls
- •2.3.4 Endoscopic Browlift Postoperative Care Pearls
- •2.4 Upper Blepharoplasty
- •2.4.1 Introduction
- •2.4.2 Patient Evaluation
- •2.4.3 Upper Blepharoplasty Anesthesia Pearls
- •2.4.4 Upper Blepharoplasty Surgical Procedure Pearls
- •2.5 Lower Blepharoplasty, Fillers, and Midface Augmentation
- •2.5.1 Introduction
- •2.5.2 Patient Evaluation
- •2.5.3 Lower Blepharoplasty Anesthesia Pearls
- •2.5.4 Lower Blepharoplasty Surgical Procedure Pearls
- •References
- •Chapter 3
- •3.1 Introduction
- •3.2 What Is the Diagnosis?
- •3.2.1 Pitfalls of Diagnosis
- •3.2.2 A Diagnostic Corticosteroid Trial?
- •3.2.3 The Question of Biopsy
- •3.3 Treatment
- •3.3.1 Corticosteroids
- •3.3.2 Radiation
- •3.3.3 Other Agents
- •3.4 Special Circumstances
- •3.4.1 Pediatric IOIS
- •3.4.2 Sclerosing Pseudotumor
- •3.4.3 Tolosa–Hunt Syndrome
- •References
- •Chapter 4
- •4.1 Introduction
- •4.2 Embryology, Anatomy, Physiology, and Pathophysiology of the Canalicular System
- •4.3 Infective Causes
- •4.3.1 Periocular Herpes Simplex Infection
- •4.3.2 Bacterial Canaliculitis
- •4.4.1 Lichen Planus
- •4.4.2 Ocular Cicatricial Pemphigoid
- •4.5 Iatrogenic Causes
- •4.5.1 Systemic Drugs
- •4.5.1.2 Docetaxel (Taxotere)
- •4.5.2 Radiotherapy
- •4.5.3 Topical Ophthalmic Treatments
- •4.5.3.2 Mitomycin C (MMC) Therapy
- •4.5.4 Lacrimal Stents and Plugs
- •4.6 The Surgical Approach to Managing Canalicular Disease
- •4.6.1 Surgical Technique for Dacryocystorhinostomy with Retrograde Canaliculostomy
- •References
- •Chapter 5
- •5.1 Introduction
- •5.2 Nomenclature
- •5.3 Clinical Manifestations of NF1
- •5.4 Orbitofacial Tumors in NF1
- •5.4.2 Malignant Peripheral Nerve Sheath Tumors
- •5.4.3 Optic Pathway Gliomas
- •5.5 Genetics
- •5.5.1 The NF1 Gene
- •5.5.2 Overlapping NF1-Like Phenotype (SPRED1)
- •5.6.1 Introduction
- •5.7 Surgical Management of Orbitofacial Tumors in NF1
- •5.7.1 Introduction
- •5.7.2 Timing of Surgery
- •5.7.3 Periorbital Involvement
- •5.7.3.1 The Upper Eyelid
- •5.7.3.2 The Lower Eyelid and Midface
- •5.7.4 Orbital Involvement
- •5.7.4.1 Proptosis
- •5.7.4.3 Proptosis Due to Optic Nerve Glioma
- •5.7.4.4 Orbital Enlargement with Dystopia and Hypoglobus
- •5.8 The Natural History of NF1 Tumor Growth from Birth to Senescence
- •References
- •Chapter 6
- •6.1 Introduction
- •6.2 Surgical Anatomy of the Lacrimal Drainage System
- •6.3 Basic Diagnostics for Disorders of the Lacrimal Drainage System
- •6.4 Selective Lacrimal Sac Biopsy in External Dacryocystorhinostomy
- •6.5.1 Case A
- •6.5.2 Case B
- •6.5.3 Case C
- •6.5.4 Case D
- •6.5.5 Case E
- •6.5.6 Case F
- •6.5.7 Case G
- •References
- •Chapter 7
- •7.1 Introduction
- •7.2 Patients and Methods
- •7.2.1 Patients
- •7.2.2 Examination
- •7.3 Results
- •7.3.1 Patient Data
- •7.3.3 Family History
- •7.3.4 Pregnancy History
- •7.3.5 Birth
- •7.3.6 Associated Systemic and Ocular Diseases
- •7.3.8 Neuroradiological Findings (Brain MRI)
- •7.3.9 Nasolacrimal System Findings
- •7.4 Discussion
- •7.4.1 Patients
- •7.4.2 Obstetric and Family History
- •7.4.3 Associated Pathologies
- •7.4.3.1 Ophthalmological Findings in Unilateral Disease
- •7.4.3.2 Neuroradiological Findings
- •7.4.3.3 Systemic Diseases
- •7.4.3.4 Nasolacrimal Duct Findings
- •7.5 Conclusions
- •References
- •Chapter 8
- •8.1 Introduction
- •8.2 Evaluation of Complicated Ptosis
- •8.2.1 Compensatory Eyebrow Elevation
- •8.2.3 Innervation Patterns of the Frontalis Muscle
- •8.2.4 Checklist of Preoperative Evaluation of Complicated Ptosis
- •8.3 Surgical Technique of Levator Muscle Recession
- •8.3.1 Principle
- •8.3.2 Approach to the Levator
- •8.3.3 Partial Levator Recession
- •8.3.4 Total Levator Recession
- •8.3.6 Undercorrection and Overcorrection
- •8.4 Surgical Technique of Brow Suspension
- •8.4.1 Materials for Brow Suspension
- •8.4.1.1 Nonautogenous Materials
- •8.4.1.2 Autogenous Fascia Lata
- •8.4.2 Our Technique of Harvesting Autogenous Fascia Lata
- •8.4.3 Mechanical Principals of Brow Suspension
- •8.4.4 Upper Lid Approach
- •8.4.5 Fascia Implantation
- •References
- •Chapter 9
- •Modern Concepts in Orbital Imaging
- •9.1 Computerized Tomography
- •9.2 Three-Dimensional Imaging
- •9.3 Magnetic Resonance Imaging
- •9.3.1 The T1 Constant
- •9.3.2 The T2 Constant
- •9.3.3 Creating the MR Image
- •9.4 Imaging of Common Orbital Lesions
- •9.4.1 Adenoid Cystic Carcinoma
- •9.4.2 Cavernous Hemangioma
- •9.4.3 Dermoid Cyst
- •9.4.4 Fibrous Dysplasia
- •9.4.5 Lymphangioma
- •9.4.6 Lymphoma
- •9.4.7 Myositis
- •9.4.8 Optic Nerve Glioma
- •9.4.9 Pseudotumor
- •9.4.10 Rhabdomyosarcoma
- •9.6 Positron Emission Tomography
- •9.7 Orbital Ultrasound
- •9.7.1 Physics and Instrumentation
- •9.7.1.1 Topographic Echography
- •9.7.1.2 Quantitative Echography
- •9.7.1.3 Kinetic Echography
- •9.7.2 Extraocular Muscles
- •9.7.3 Optic Nerves
- •References
- •Chapter 10
- •10.1 Introduction
- •10.3 Etiology
- •10.4 Microbiology
- •10.5 Changing Pathogens and Resistance
- •10.5.2 Orbital MRSA
- •10.6 Evaluation of Orbital Cellulitis
- •10.7 Medical Treatment of Orbital Cellulitis
- •10.8 Surgical Treatment of Orbital Cellulitis
- •10.9 Prevention of Orbital Cellulitis After Orbital Fracture
- •References
- •Chapter 11
- •11.1 Clinical Picture
- •11.1.1 Clinical Phases
- •11.2 Ocular Complications
- •11.3 Investigation
- •11.3.1 Angiography
- •11.4 Management
- •11.4.1 Active Nonintervention
- •11.4.2 Indications for Treatment
- •11.5 Modalities of Treatment
- •11.5.1 Steroids
- •11.5.1.1 Topical Steroids
- •11.5.1.2 Intralesional Corticosteroid Injection
- •11.5.1.3 Oral Corticosteroids
- •11.5.2 Interferon-Alfa
- •11.5.3 Vincristine
- •11.5.4 Laser
- •11.5.5 Embolization
- •11.5.6 Surgery
- •References
- •Chapter 12
- •12.1 Introduction
- •12.2 Epidemiology
- •12.3 Biological Behavior and Timing of Metastasis
- •12.4 Lateralization
- •12.5 Localization
- •12.6 Clinical Features
- •12.7 Imaging and Patterns of Orbital Metastatic Disease
- •12.8 Biopsy
- •12.9 Common Types of Orbital Metastases
- •12.9.1 Breast Carcinoma
- •12.9.2 Lung Carcinoma
- •12.9.3 Prostatic Cancer
- •12.9.4 Melanoma
- •12.9.5 Carcinoid Tumor
- •12.11 Treatment
- •12.11.1 Radiotherapy
- •12.11.2 Chemotherapy
- •12.11.3 Hormonal Therapy
- •12.11.4 Surgery
- •12.12 Prognosis and Survival
- •References
- •Chapter 13
- •13.1 Introduction
- •13.2 Rituximab
- •13.3 Yttrium-90-Labeled Ibritumomab Tiuxetan
- •13.4 Imatinib Mesylate
- •13.5 Cetuximab
- •References
- •Chapter 14
- •14.1 Introduction
- •14.2 Porous Orbital Implants
- •14.3 Orbital Implant Selection in Adults
- •14.4 Orbital Implant Selection in Children
- •14.5 Volume Considerations in Orbital Implant Selection
- •14.7 Which Wrap to Use
- •14.8 To Peg or Not to Peg Porous Implants
- •14.9 Summary
- •References
- •Chapter 15
- •15.1 Introduction
- •15.2 Etiology and Presentation
- •15.2.1 Etiology of Orbital Volume Loss
- •15.2.2 Etiology of Periorbital Volume Loss
- •15.2.3 Features of Orbital Volume Loss
- •15.2.4 Features of Periorbital Volume Loss
- •15.3 Background to Injectable Soft-Tissue Fillers
- •15.3.1 Historical Perspective on Volume Replacement
- •15.4 Types of Injectable Soft-Tissue Filler
- •15.4.1 Collagen Fillers
- •15.4.2 Hyaluronic acid Fillers
- •15.5 Treatment Areas
- •15.5.1 Orbit
- •15.5.2 Upper Eyelid and Brow
- •15.5.3 Tear Trough
- •15.5.4 Temple and Brow
- •15.6 Other Periorbital Uses of Injectable Soft-Tissue Fillers
- •15.6.1 Upper Eyelid Loading
- •15.6.2 Lower Eyelid Elevation
- •15.6.3 Treatment of Cicatricial Ectropion
- •15.7 Future Developments
- •References
86 |
5 Orbitofacial Neurofibromatosis 1: Current Medical and Surgical Management |
5.7.4Orbital Involvement
5.7.4.1Proptosis
5Orbital enlargement resulting from growth of an optic nerve glioma or neurofibomas is common. It may also be
due to bony cranial abnormalities, typically sphenoid wing dysplasia. The last results in the classic finding of
pulsatile proptosis in the patient with NF1. In addition, buphthalmos, which is often secondary to congenital glaucoma associated with NF1, can lead to pseudoproptosis from an increased axial length. It is not uncommon for patients with significant orbital involvement to have a cluster of findings, including sphenoid wing dysplasia, proptosis, ptosis, buphthalmos with a blind eye, and an optic nerve glioma or orbital neurofibroma (Fig. 5.5).
a |
b |
c |
d |
e |
f |
g |
h |
Fig. 5.5 (a) Neonatal picture of infant with NF1 tumors present at birth. (b) T2 MRI demonstrates neurofibromas present in orbit and lids as well as a buphthalmic globe causing proptosis from an increased axial length as well as intraorbital masses. (c) Child at age 2½ years postenucleation at another institution with a significant recurrence of proptosis and lid deformity secondary to a marked increase in tumor growth. (d) MRI now shows orbital implant surrounded by an increase in neurofibromas extending into the upper lid. (e) Lid crease incision used to debulk upper lid and orbital tumors with wedge resection of one third lateral lid and canthal reconstruction; note thickening of lateral tarsal lid margin due to infiltration of diffuse type of neurofibroma. (f) Resection of levator muscle infiltrated with plexiform and diffuse neurofibromas. (g) Four years postoperative. (h) MRI postop debulking and lid reconstruction with prosthesis in place
5.7 Surgical Management of Orbitofacial Tumors in NF1 |
87 |
A multidisciplinary approach is best for the NF1 patient afflicted with these complicated disfiguring problems. Even after neurooncological evaluation and treatment, it is often necessary to intervene surgically to rehabilitate a patient’s appearance. For the child with gross orbital and periorbital deformities, this may be of even greater concern to the family than the preservation of the eye on the affected side despite the opportunity for a reasonable visual potential. The surgeon must thoroughly discuss the realistic limits to keeping a proptotic eye versus complete resection (enucleation, etc.) with subsequent socket reconstruction.
The approach to the proptotic patient with NF1 may require craniofacial or neurosurgical collaboration depending on the need to reach a specific area of the orbit. For posterior apical lesions or the repair of certain bony abnormalities of the orbit and cranium, a transcranial neurosurgical approach may be warranted. Other options for treating proptosis in NF1 are usually available to avoid unnecessarily aggressive intervention, such as orbital exenteration for rehabilitation. As stated, we strongly reject use of this technique except for an extremely unusual case for which malignancy is of documented concern. With a carefully staged approach to multiple surgeries, reasonable results can be achieved to optimize ocular prosthesis retention with acceptable or even good cosmesis in many cases.
5.7.4.2Proptosis Due to Orbital Neurofibromas
Patients with orbital neurofibromas, particularly of the plexiform type, may benefit from possible reduction of tumor with additional chemotherapy. To this date, however, no chemotherapy regimen has proven effective in completely reducing orbital neurofibromas [4]. The main effect, as stated, has been possible slowed growth. At this time, for patients with significant orbital involvement, surgery remains the most hopeful modality for addressing issues of painful proptosis or disfigurement. Patients may suffer from exposure due to proptosis and from orbital or periorbital discomfort secondary to their orbitofacial neurofibromas. The surgeon must obtain adequate imaging in such cases to delineate the presence of any intracranial extension as well as any additional intracranial tumors or other pathology.
5.7.4.3Proptosis Due to Optic Nerve Glioma
The medical management and controversies regarding tumor classification of OPGs in NF1 have been addressed in this chapter. In addition to medical management,
Fig. 5.6 Optic nerve glioma excision: lateral approach. Gliomas can often be excised via a lateral orbitotomy as demonstrated above. Glioma visible in front of retractor (see arrow). Removal of the lateral wall in children may not be necessary due to the shallow orbit in this age group (From Katowitz [23]. With permission from Springer)
tumor resection may be considered. This is both to treat disfiguring proptosis and to remove a lesion that could potentially grow posteriorly. Gliomas of the orbital optic nerve causing proptosis can often be removed by a lateral approach, especially in children, for whom the orbit is shallower and removal of the orbital bone can be avoided (Fig. 5.6). Gliomas directly behind the globe can sometimes be removed by an anterior approach combined with enucleation (Fig. 5.7). For posterior lesions where there is severe proptosis or real concern regarding retrograde progression, a superior transcranial neurosurgical approach may be required (Fig. 5.8).
5.7.4.4Orbital Enlargement with Dystopia and Hypoglobus
Early involvement of NF1 tumors can lead to orbital enlargement (Fig. 5.9). This can present a significant surgical dilemma for reconstruction. Debulking of tumor from the orbit early in life may decrease the stimulus for asymmetric growth to some degree but is usually not sufficient to control this effectively. Orbital bony enlargement, while a problem, is often less noticeable than the soft tissue deformities usually associated with this. For the casual observer, the increase in orbital volume is actually hidden. The periorbital soft tissue changes are what is noticeable, represented by a higher and often more prominent brow, a lengthened lid fissure with lid deformities secondary to tumor growth, as well as an associated mechanical ptosis. Bony sphenoid wing dysplasia or even aplasia permits visible pulsations transmitted from the brain through the orbital defect.
88 |
5 Orbitofacial Neurofibromatosis 1: Current Medical and Surgical Management |
Fig. 5.7 Optic nerve glioma excision: anterior approach. Gliomas can be excised using an anterior approach combined with enucleation if
5 the tumor is adherent to the globe and not in the posterior orbit. (a) Marked proptosis with exposure problems. (b) Tumor visible after removing extraocular muscles. (c) Four years postoperative
a
c
b
d
a |
b |
c |
d |
e |
Fig. 5.8 Optic nerve glioma excision: superior approach. For posterior tumors, particularly if there is concern for retrograde progression, a transcranial neurosurgical approach may be utilized. (a) Left proptosis from optic nerve glioma. (b) MRI scan of tumor near bony canal entrance posteriorly. (c) Frontal lobe retracted and periorbita exposed after removing orbital roof. (d) Artist rendition of a superior orbitotomy with retraction of the levator muscle and superior rectus medially (From Katowitz [23]. With permission from Springer). (e) Ten years postoperative
|
5.7 |
Surgical Management of Orbitofacial Tumors in NF1 |
89 |
a |
b |
c |
|
d |
e |
f |
g
Fig. 5.9 Orbital enlargement with vertical dystopia and hypoglobus. (a) A 20-month old child presenting with ptosis of his left upper lid. (b) At 20 years of age, despite multiple efforts to debulk orbital and periorbital tumors, including enucleation with a dermis fat graft, he still has obvious dystopia and hypoglobus. Note the heavy tumors in his left cheek; note also the paste-on hairpiece used to cover hair loss over lateral cranium. (c) T2 MRI scan shows expansion of orbit in all directions secondary to tumor growth. This patient declined osteotomies at an earlier age. (d) CT scan reveals thin bony orbital structure that would be difficult to mobilize and support with bone grafts and hardware at this point in time; note also the posterior bony defect due to sphenoid bone dysplasia. (e) Tumor excision from cheek via a skin flap with rhytidectomy. Further ptosis and lid reconstruction also done. (f) One month postoperative with positive effect from rhytidectomy but persistent vertical dystopia. Paste-on hairpiece withheld to avoid contaminating rhytidectomy incision. (g) An appropriate base-down prism can be used to optically elevate orbit for a more symmetrical appearance
